STX11 (Syntaxin 11) is a member of the syntaxin family of SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) proteins. It is encoded by the STX11 gene located on chromosome 6p21.31 and plays essential roles in intracellular membrane fusion events. Unlike neuronal syntaxins (STX1-4), STX11 is primarily expressed in immune cells and non-neuronal tissues, with lower expression in certain brain regions. STX11 is particularly important for intracellular trafficking in hematopoietic cells, where it regulates granule secretion, lysosomal trafficking, and endosomal fusion. Emerging research suggests that STX11 may have roles in neurodegenerative diseases through effects on membrane trafficking pathways relevant to Alzheimer's disease and Parkinson's disease pathogenesis. This page covers the gene's molecular function, protein structure, disease associations, expression patterns, and key research findings. [1][2]
| Property | Value |
|---|---|
| Gene Symbol | STX11 |
| Full Name | Syntaxin 11 |
| Chromosomal Location | 6p21.31 |
| Ensembl ID | ENSG00000139289 |
| NCBI Gene ID | 6756 |
| OMIM | 604396 |
| UniProt ID | O75560 |
| Protein Length | 288 amino acids |
| Molecular Weight | ~32 kDa |
STX11 is a tail-anchored membrane protein with several distinct structural features:
The N-terminal region of STX11 contains a three-helix bundle that regulates SNARE complex formation. This domain can fold back onto the SNARE motif to inhibit premature complex assembly, providing a regulatory mechanism for controlling membrane fusion timing.
The central SNARE motif (approximately 60-70 amino acids) forms the core of the SNARE complex. This region contains characteristic heptad repeats that coil into a alpha-helical bundle. The SNARE motif of STX11 contributes to the formation of ternary SNARE complexes with SNAP proteins and vesicle-associated SNAREs (v-SNAREs).
The C-terminal transmembrane domain anchors STX11 to intracellular membranes. Unlike many SNAREs, STX11 is a tail-anchored protein, meaning the transmembrane domain is at the C-terminus and insertion occurs post-translationally into the membrane.
STX11 contains a proline-rich region that may serve as a docking site for SH3 domain-containing proteins, potentially linking STX11 function to signaling pathways.
STX11 functions as a Qc-SNARE (glutamine-containing SNARE) in the formation of SNARE complexes:
STX11 participates in several trafficking pathways:
STX11 exhibits a tissue-specific expression pattern:
| Tissue/Cell Type | Expression Level |
|---|---|
| Spleen | High |
| Lung | Moderate |
| Bone Marrow | Moderate |
| Kidney | Low-Moderate |
| Brain (microglia) | Low |
| Neurons | Very Low |
| T cells | High |
| NK cells | High |
| Macrophages | Moderate |
In the brain, STX11 expression is primarily detected in microglia, the immune cells of the central nervous system, rather than neurons or astrocytes. This microglial expression may be relevant to neurodegenerative disease processes.
While STX11 is not highly expressed in neurons, emerging research suggests potential connections to Alzheimer's disease:
Microglial Function: STX11 is expressed in brain microglia where it may regulate phagocytic activity and clearance of amyloid-beta plaques. Dysregulated microglial function is a key feature of AD pathogenesis, and STX11 variants might affect this process.
Membrane Trafficking: Altered endosomal and lysosomal trafficking is observed in AD. STX11's role in these pathways could influence amyloid precursor protein (APP) processing and amyloid-beta clearance.
Genetic Associations: Some GWAS studies have suggested potential links between STX11 variants and AD risk, though findings are not yet robust.
STX11 may have relevance to PD through several mechanisms:
Lysosomal Function: PD is associated with lysosomal dysfunction. STX11's role in lysosomal trafficking could influence alpha-synuclein clearance and aggregation.
Autophagy: Impaired autophagic flux is observed in PD. STX11 contributes to autophagosome-lysosome fusion, and altered function could affect protein aggregate clearance.
Immune Response: STX11 variants may affect microglial inflammatory responses in PD.
STX11 mutations are directly associated with familial hemophagocytic lymphohistiocytosis type 4 (FHL4), a severe immune disorder:
Altered STX11 expression has been reported in various cancers:
Mus musculus: Stx11 knockout mice exhibit:
Zebrafish: Used to study STX11 function in immune cell development and trafficking.
STX11 is clinically relevant in several contexts: